AstraZeneca Plc is to pay up to $443 million to acquire Omthera Pharmaceuticals Inc of Princeton, New Jersey, a five-year-old company with a single product – a late stage omega-3 free fatty acid composition to treat hypertriglyceridaemia. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
